
|Articles|April 25, 2004
MTOPS, AUA guidelines continue to shape BPH Tx
Dallas--The two most significant developments in the management of benignprostatic hyperplasia in the past year were the release of the AUA updateof clinical guidelines for the condition and analysis of data from the MedicalTherapy of Prostatic Symptoms (MTOPS) trial, said Claus G. Roehrborn, MD,professor and chairman of the department of urology, University of TexasSouthwestern Medical Center, Dallas.
Advertisement
Advertisement
Related Content
Latest CME
Advertisement
Advertisement
Trending on Urology Times
1
FDA approves lutetium Lu 177 vipivotide tetraxetan for PSMA-positive mHSPC
2
Laura Bukavina, MD, and Gabriela Díaz, MD, on the rise of young-onset bladder cancer
3
Individualizing androgen pathway therapy in mCSPC
4
BOND-003 Cohort C: Efficacy Results
5







